ASX
LCT 0.051   Last updated 3.53 am
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheets provide a summary of our current business and research pipeline.

Living Cell Technologies (LCT)

Living Cell Technologies is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need.

 

Our treatments are based on cell encapsulation and implantation for human therapeutics. We currently have two products in clinical development: DIABECELL® for the treatment of type 1 diabetes which is in late stage clinical trials and NTCELL® which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease.

 

Living Cell Technologies leads the world in cell transplant research. Our product pipeline consists of cell therapies developed from cells sourced from a unique herd of disease-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands.

 

Our unique proprietary technology, IMMUPEL™, coats cells with protective capsules that prevent attacks by the patient’s immune system. This allows the use of cell therapies without the need for co-treatment with drugs that suppress the immune system, which often have negative side effects.

— 30 July 2014

Appendix 4C Quarterly Report

Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 30 June 2014. The company ended the quarter with a cash balance of $4,554,000 compared to $5,765,000 last quarter.

Read More Read Less

— 8 July 2014

Dr Ken Taylor Appointed Chief Executive

Dr Ken Taylor has been appointed Chief Executive of Living Cell Technologies. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More
— 8 May 2014

There are no forthcoming events at present.

Load More
Announcements

— 30 July 2014

Appendix 4C Quarterly Report

Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 30 June 2014. The company ended the quarter with a cash balance of $4,554,000 compared to $5,765,000 last quarter.

Read More Read Less

— 8 July 2014

Dr Ken Taylor Appointed Chief Executive

Dr Ken Taylor has been appointed Chief Executive of Living Cell Technologies. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events
— 8 May 2014

There are no forthcoming events at present.

Load More
© 2014 Living Cell Technologies Limited.
site by { brownpaperbag }